Regulatory/Effector T-Cell ratio is reduced in coronary artery disease

Circulation Journal

Volumn 78, Issue 12, 2014, Pages 2935-2941

  Emoto, Takuo ^a   Sasaki, Naoto ^a   Yamashita, Tomoya ^a   Kasahara, Kazuyuki ^a   Yodoi, Keiko ^a   Sasaki, Yoshihiro ^a   Matsumoto, Takuya ^a   Mizoguchi, Taiji ^a   Hirata, Ken Ichi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Coronary artery disease; Immune system; Regulatory T cell

Indexed keywords

C REACTIVE PROTEIN; CD45RA ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 2 RECEPTOR ALPHA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRANSCRIPTION FACTOR FOXP3; GLUCOSE BLOOD LEVEL; LIPID; T LYMPHOCYTE ANTIGEN;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL FRACTIONATION; CELL POPULATION; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; STABLE ANGINA PECTORIS; AGING; ANALYSIS; ANGINA PECTORIS; ATHEROSCLEROSIS; BLOOD; COMPARATIVE STUDY; GLUCOSE BLOOD LEVEL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MIDDLE AGED; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; AGING; ANGINA PECTORIS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ATHEROSCLEROSIS; BLOOD GLUCOSE; FEMALE; HUMANS; LIPIDS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84911872032     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0644     Document Type: Article

References (22)

1. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340: 115-126.
2. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 2013; 368: 2004-2013.
3. Simon DI. Inflammation and vascular injury: Basic discovery to drug development. Circ J 2012; 76: 1811-1818.
4. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12: 204-212.
5. Ozaki Y, Imanishi T, Taruya A, Aoki H, Masuno T, Shiono Y, et al. Circulating CD14+CD16+ monocyte subsets as biomarkers of the severity of coronary artery disease in patients with stable angina pectoris. Circ J 2012; 76: 2412-2418.
6. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, Zoll J, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006; 12: 178-180.
7. Sasaki N, Yamashita T, Takeda M, Shinohara M, Nakajima K, Tawa H, et al. Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice. Circulation 2009; 120: 1996-2005.
8. Takeda M, Yamashita T, Sasaki N, Nakajima K, Kita T, Shinohara M, et al. Oral administration of an active form of vitamin D3 (calcitriol) decreases atherosclerosis in mice by inducing regulatory T cells and immature dendritic cells with tolerogenic functions. Arterioscler Thromb Vasc Biol 2010; 30: 2495-2503.
9. Klingenberg R, Gerdes N, Badeau RM, Gistera A, Strodthoff D, Ketelhuth DF, et al. Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis. J Clin Invest 2013; 123: 1323-1334.
10. Kita T, Yamashita T, Sasaki N, Kasahara K, Sasaki Y, Yodoi K, et al. Regression of atherosclerosis with anti-CD3 antibody via augmenting a regulatory T-cell response in mice. Cardiovasc Res 2014; 102: 107-117.
11. Sasaki N, Yamashita T, Takeda M, Hirata K. Regulatory T cells in atherogenesis. J Atheroscler Thromb 2012; 19: 503-515.
12. Kasahara K, Sasaki N, Yamashita T, Kita T, Yodoi K, Sasaki Y, et al. CD3 antibody and IL-2 complex combination therapy inhibits atherosclerosis by augmenting a regulatory immune response. J Am Heart Assoc 2014; 3: e000719, doi: 10. 1161/JAHA. 113. 000719.
13. Mor A, Luboshits G, Planer D, Keren G, George J. Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J 2006; 27: 2530-2537.
14. Ammirati E, Cianflone D, Banfi M, Vecchio V, Palini A, De Metrio M, et al. Circulating CD4+CD25 hiCD127lo regulatory T-cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30: 1832-1841.
15. Wigren M, Bjorkbacka H, Andersson L, Ljungcrantz I, Fredrikson GN, Persson M, et al. Low levels of circulating CD4+FoxP3+ T cells are associated with an increased risk for development of myocardial infarction but not for stroke. Arterioscler Thromb Vasc Biol 2012; 32: 2000-2004.
16. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133: 775-787.
17. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009; 30: 899-911.
18. Liuzzo G, Biasucci LM, Trotta G, Brugaletta S, Pinnelli M, Digianuario G, et al. Unusual CD4+CD28null T lymphocytes and recurrence of acute coronary events. J Am Coll Cardiol 2007; 50: 1450-1458.
19. Giubilato S, Liuzzo G, Brugaletta S, Pitocco D, Graziani F, Smaldone C, et al. Expansion of CD4+CD28null T-lymphocytes in diabetic patients: Exploring new pathogenetic mechanisms of increased cardiovascular risk in diabetes mellitus. Eur Heart J 2011; 32: 1214-1226.
20. Dietel B, Cicha I, Voskens CJ, Verhoeven E, Achenbach S, Garlichs CD. Decreased numbers of regulatory T cells are associated with human atherosclerotic lesion vulnerability and inversely correlate with infiltrated mature dendritic cells. Atherosclerosis 2013; 230: 92-99.
21. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
22. Maganto-Garcia E, Tarrio ML, Grabie N, Bu DX, Lichtman AH. Dynamic changes in regulatory T cells are linked to levels of dietinduced hypercholesterolemia. Circulation 2011; 124: 185-195.